Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
复制标题
DOI：
10.1182/blood-2013-12-541953
复制
发表时间：
2014-05-08
期刊：
影响因子：
20.3
通讯作者：
Geisler, Christian H.
中科院分区：
文献类型：
--
作者：
Kolstad, Arne;Laurell, Anna;Geisler, Christian H.
MCL3研究的主要目标是通过在高剂量方案中添加90 Y-ibritumomab-tiuxetan(Zvalin)来改善移植前未完全缓解(CR)的患者的预后。160例未经治疗的II-IV期套细胞淋巴瘤患者
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90 Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients